Drugmaker Novo Nordisk has released two new trial results that could strengthen the case for insurers and government agencies to cover the cost of Wegovy, its popular but expensive weight-loss treatment. Patients taking the drug maintained an average 10% weight loss after four years, and results from a previous trial showed that Wegovy reduced the risk of serious heart problems, such as strokes and heart attacks, by 20%

"This is the longest study we've conducted so far of semaglutide for weight loss," said Martin Holst Lange, Novo's head of development, referring to the active ingredient in Wegovy and the company's diabetes drug Ozempic. "We see that once the majority of the weight loss is accrued; you don't go back and start to increase in weight if you stay on the drug."

Continue Reading for Free

Register and gain access to:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.